Johnson & Johnson (JNJ) News

Johnson & Johnson delivered a solid start to the fiscal year with robust top-line operational growth. Despite facing biosimilar competition for its blockbuster drug Stelara, the healthcare giant capitalized on the rapid commercial launch of its newly approved oral plaque psoriasis therapy Icotyde and sustained momentum in its cardiovascular MedTech portfolio. This performance reinforces management's confidence in its upgraded full-year financial guidance and long-term expansion goals.

J&J’s stock narrative is being driven by its transformation into a focused healthcare platform, where MedTech mix improvements and oncology franchise strength can stabilize earnings through a shifting drug landscape.

Johnson & Johnson is guiding to a major 2026 revenue milestone, but two uncertainties can still interrupt the growth-to-margin story: ongoing talc litigation outcomes and tariff-driven MedTech cost pressure that the company flags as material.